RhumbLine Advisers’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $56.8M | Sell |
262,979
-12,459
| -5% | -$2.38M | 0.04% | 347 |
|
|
2026
Q1 | $50.5M | Buy |
275,438
+3,692
| +1% | +$680K | 0.04% | 357 |
|
|
2025
Q4 | $47.8M | Sell |
271,746
-17,460
| -6% | -$2.85M | 0.04% | 363 |
|
|
2025
Q3 | $40.5M | Sell |
289,206
-10,941
| -4% | -$1.48M | 0.03% | 444 |
|
|
2025
Q2 | $37.7M | Buy |
300,147
+3,853
| +1% | +$480K | 0.03% | 457 |
|
|
2025
Q1 | $40.5M | Buy |
296,294
+27,703
| +10% | +$3.96M | 0.04% | 407 |
|
|
2024
Q4 | $41.1M | Sell |
268,591
-5,718
| -2% | -$964K | 0.04% | 398 |
|
|
2024
Q3 | $53.2M | Sell |
274,309
-9,897
| -3% | -$2.07M | 0.05% | 325 |
|
|
2024
Q2 | $65.9M | Buy |
284,206
+5,562
| +2% | +$1.21M | 0.06% | 261 |
|
|
2024
Q1 | $60.1M | Buy |
278,644
+597
| +0.2% | +$140K | 0.06% | 288 |
|
|
2023
Q4 | $72M | Sell |
278,047
-505
| -0.2% | -$124K | 0.08% | 231 |
|
|
2023
Q3 | $71.6M | Sell |
278,552
-2,184
| -0.8% | -$584K | 0.08% | 211 |
|
|
2023
Q2 | $80M | Buy |
280,736
+956
| +0.3% | +$285K | 0.09% | 198 |
|
|
2023
Q1 | $77.8M | Buy |
279,780
+1,175
| +0.4% | +$325K | 0.1% | 193 |
|
|
2022
Q4 | $77.2M | Buy |
278,605
+5,359
| +2% | +$1.51M | 0.1% | 181 |
|
|
2022
Q3 | $73M | Buy |
273,246
+10,082
| +4% | +$2.14M | 0.11% | 167 |
|
|
2022
Q2 | $53.7M | Buy |
263,164
+12,204
| +5% | +$2.49M | 0.08% | 231 |
|
|
2022
Q1 | $52.9M | Sell |
250,960
-22,739
| -8% | -$4.94M | 0.07% | 254 |
|
|
2021
Q4 | $65.7M | Buy |
273,699
+4,266
| +2% | +$1.1M | 0.08% | 214 |
|
|
2021
Q3 | $76.2M | Sell |
269,433
-4,906
| -2% | -$1.61M | 0.1% | 170 |
|
|
2021
Q2 | $95M | Sell |
274,339
-19,578
| -7% | -$5.93M | 0.12% | 142 |
|
|
2021
Q1 | $82.2M | Sell |
293,917
-15,559
| -5% | -$4.2M | 0.11% | 151 |
|
|
2020
Q4 | $75.8M | Sell |
309,476
-43,308
| -12% | -$11.2M | 0.1% | 159 |
|
|
2020
Q3 | $100M | Sell |
352,784
-4,405
| -1% | -$1.23M | 0.16% | 125 |
|
|
2020
Q2 | $95.6M | Buy |
357,189
+1,672
| +0.5% | +$503K | 0.16% | 123 |
|
|
2020
Q1 | $112M | Buy |
355,517
+3,818
| +1% | +$1.16M | 0.24% | 83 |
|
|
2019
Q4 | $104M | Sell |
351,699
-2,052
| -0.6% | -$569K | 0.17% | 112 |
|
|
2019
Q3 | $82.4M | Sell |
353,751
-3,282
| -0.9% | -$764K | 0.15% | 138 |
|
|
2019
Q2 | $83.5M | Buy |
357,033
+20,925
| +6% | +$4.83M | 0.16% | 123 |
|
|
2019
Q1 | $79.4M | Buy |
336,108
+11,441
| +4% | +$3.6M | 0.15% | 125 |
|
|
2018
Q4 | $97.7M | Sell |
324,667
-1,464
| -0.4% | -$467K | 0.21% | 88 |
|
|
2018
Q3 | $115M | Sell |
326,131
-19,129
| -6% | -$6.59M | 0.22% | 84 |
|
|
2018
Q2 | $100M | Buy |
345,260
+5,754
| +2% | +$1.62M | 0.2% | 94 |
|
|
2018
Q1 | $93M | Sell |
339,506
-6,966
| -2% | -$2.16M | 0.19% | 103 |
|
|
2017
Q4 | $110M | Buy |
346,472
+7,395
| +2% | +$2.37M | 0.22% | 90 |
|
|
2017
Q3 | $106M | Buy |
339,077
+3,821
| +1% | +$1.13M | 0.23% | 85 |
|
|
2017
Q2 | $91M | Sell |
335,256
-3,376
| -1% | -$893K | 0.21% | 96 |
|
|
2017
Q1 | $92.6M | Sell |
338,632
-29,033
| -8% | -$8.21M | 0.22% | 90 |
|
|
2016
Q4 | $104M | Buy |
367,665
+10,301
| +3% | +$3.05M | 0.26% | 70 |
|
|
2016
Q3 | $112M | Buy |
357,364
+8,533
| +2% | +$2.53M | 0.31% | 61 |
|
|
2016
Q2 | $84.4M | Buy |
348,831
+14,612
| +4% | +$3.85M | 0.25% | 78 |
|
|
2016
Q1 | $87M | Buy |
334,219
+8,921
| +3% | +$2.36M | 0.27% | 70 |
|
|
2015
Q4 | $99.7M | Sell |
325,298
-11,589
| -3% | -$3.33M | 0.32% | 59 |
|
|
2015
Q3 | $98.3M | Buy |
336,887
+2,454
| +0.7% | +$810K | 0.33% | 58 |
|
|
2015
Q2 | $135M | Sell |
334,433
-56,632
| -14% | -$22.7M | 0.43% | 43 |
|
|
2015
Q1 | $165M | Sell |
391,065
-6,863
| -2% | -$2.7M | 0.48% | 40 |
|
|
2014
Q4 | $135M | Sell |
397,928
-7,139
| -2% | -$2.31M | 0.39% | 50 |
|
|
2014
Q3 | $134M | Sell |
405,067
-2,242
| -0.6% | -$739K | 0.4% | 46 |
|
|
2014
Q2 | $128M | Sell |
407,309
-18,878
| -4% | -$5.68M | 0.38% | 48 |
|
|
2014
Q1 | $130M | Sell |
426,187
-7,829
| -2% | -$2.49M | 0.39% | 50 |
|
|
2013
Q4 | $121M | Sell |
434,016
-10,460
| -2% | -$2.71M | 0.36% | 55 |
|
|
2013
Q3 | $107M | Sell |
444,476
-8,124
| -2% | -$1.82M | 0.33% | 60 |
|
|
2013
Q2 | $97.4M | Buy |
+452,600
| New | +$96.7M | 0.31% | 61 |
|
Other funds holding BIIB
RhumbLine Advisers's BIIB Position: Q2 2026 in Review
RhumbLine Advisers reduced its Biogen (BIIB) stake by 4.5% in Q2 2026, selling an estimated $2.38M and leaving 262,979 shares worth $56.8M. The position accounts for 0.04% of the portfolio, ranked #347.
RhumbLine Advisers first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $165M in Q1 2015. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- RhumbLine Advisers held 262,979 shares of Biogen worth $56.8M as of Q2 2026.
- RhumbLine Advisers sold 12,459 Biogen shares in Q2 2026, an estimated $2.38M.
- Biogen made up 0.04% of RhumbLine Advisers's portfolio in Q2 2026, its #347 holding.
- RhumbLine Advisers first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Biogen position peaked at $165M in Q1 2015.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.